Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Return on Assets data on record, last reported at 0.0% in Q1 2026.

  • On a quarterly basis, Return on Assets changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Assets reached 0.0% in Q1 2026 per IKT's latest filing, up from 0.0% in the prior quarter.
  • Over the last five years, Return on Assets for IKT hit a ceiling of 0.0% in Q1 2026 and a floor of 0.03% in Q3 2024.
  • A 5-year average of 0.01% and a median of 0.01% in 2025 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: dropped -2bps in 2024, then increased 2bps in 2025.
  • Tracing IKT's Return on Assets over 5 years: stood at 0.01% in 2022, then crashed by -83bps to 0.01% in 2023, then surged by 55bps to 0.01% in 2024, then increased by 28bps to 0.0% in 2025, then grew by 22bps to 0.0% in 2026.
  • Business Quant data shows Return on Assets for IKT at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.01% in Q3 2025.